Senior Director of Enterprise AI Scaling and Innovation

Lead global rollout and operational execution of the NOVA AI program across four Lilly organizations, shaping and scaling AI initiatives to enterprise production with accountability for governance and value realization.

Drive critical cross-functional AI initiatives including frontier programs like SAGE, managing technical feasibility, architecture, and institutional dependencies for enterprise-wide AI adoption.

Maintain active oversight of the external AI landscape, evaluating technologies and startups to accelerate external innovation and integrating findings into enterprise AI strategy.

Postgraduate degree (MBA, MSc, M.Pharm) or equivalent professional experience required.

15+ years of progressive leadership in enterprise strategy, transformation and technology, including substantial experience leading AI initiatives in pharma, healthcare, life sciences, or regulated global enterprises.

Proven track record of deploying AI at enterprise scale from concept to production with measurable business impact, including technical leadership and governance expertise.

Deep technical expertise across AI/gen-AI lifecycles (LLMs, agentic systems, evaluation), sufficient to assess feasibility and architecture; not a hands-on engineering role but demands substantial technical depth.

Senior technical leader with proven ability to challenge and redirect executive-sponsored AI projects within large, matrixed global organizations or Global Capability Centers.

Experienced in enterprise AI governance balancing speed, risk, and compliance, with strong executive communication and the ability to influence diverse senior stakeholders.

Background in evaluating and fast-tracking external AI technology partnerships, working effectively with procurement, legal, and security to accelerate co-innovation adoption.